Key result
Flecainide testing for Brugada syndrome may lack reproducibility during subsequent patient tests.
Why the study?
Class I antiarrhythmic drug infusion is the standard test to unmask Brugada syndrome, but reproducibility of positive flecainide response is uncertain.
Is a positive flecainide test reproducible in subsequent testing in patients with Brugada syndrome?
Is a positive flecainide test reproducible in subsequent testing in patients with Brugada syndrome?
A positive flecainide challenge test in Brugada syndrome may not always be reproducible upon subsequent testing.
Answers are grounded in this paper and cite their sources.
Non-reproducible flecainide responses suggest diagnostic caution in Brugada syndrome; leaves open test reliability for prospective validation.
Class I antiarrhythmic drug infusion has been established as the standard test to unmask Brugada syndrome. This report presents two patients with Brugada syndrome with positive flecainide response which was not reproducible in a subsequent test.
No takes yet. Share an insight, caveat, or question.
Abello et al. (2006) studied this question. Flecainide testing for Brugada syndrome may lack reproducibility, as evidenced by two patients whose initial positive responses were negative in subsequent tests.
Synapse has enriched 10 related papers. Consider them for comparative context: